Similar articles

• Are ABVD and MOPP/ABV truly equivalent for treating Hodgkin's disease at advanced stages?

  Andrieu JM, Colonna P. Andrieu JM, et al. J Clin Oncol. 1998 Jun;16(6):2283. J Clin Oncol. 1998. PMID: 9626234 Clinical Trial. No abstract available.
• Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.

  Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM, Canellos GP, Peterson BA. Duggan DB, et al. J Clin Oncol. 2003 Feb 15;21(4):607-14. doi: 10.1200/JCO.2003.12.086. J Clin Oncol. 2003. PMID: 12586796 Clinical Trial.
• [Successful chemotherapy of cancer. Remission of Hodgkin's disease. IV].

  Lopez M. Lopez M. Clin Ter. 2001 May-Jun;152(3):203-6. Clin Ter. 2001. PMID: 11692542 Italian. No abstract available.
• Advanced Hodgkin's disease: ABVD is better, yet is not good enough!

  Diehl V. Diehl V. J Clin Oncol. 2003 Feb 15;21(4):583-5. doi: 10.1200/JCO.2003.11.072. J Clin Oncol. 2003. PMID: 12586791 Review. No abstract available.
• Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.

  Ansell SM. Ansell SM. Am J Hematol. 2016 Jan;91(1):109-12. doi: 10.1002/ajh.24226. Epub 2015 Nov 26. Am J Hematol. 2016. PMID: 26505486 Review.